Compare UI & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UI | ONC |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3B | 34.8B |
| IPO Year | 2011 | N/A |
| Metric | UI | ONC |
|---|---|---|
| Price | $750.32 | $362.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $623.50 | $370.25 |
| AVG Volume (30 Days) | 106.4K | ★ 194.9K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | ★ 103.11 | N/A |
| EPS | ★ 7.29 | N/A |
| Revenue | ★ $2,573,545,000.00 | N/A |
| Revenue This Year | $31.14 | $900.30 |
| Revenue Next Year | $14.87 | $21.97 |
| P/E Ratio | ★ $102.92 | $614.06 |
| Revenue Growth | ★ 33.45 | N/A |
| 52 Week Low | $255.00 | $196.53 |
| 52 Week High | $803.60 | $385.22 |
| Indicator | UI | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 72.13 | 60.90 |
| Support Level | $692.09 | $345.04 |
| Resistance Level | $736.52 | $365.60 |
| Average True Range (ATR) | 40.22 | 10.14 |
| MACD | 10.88 | 0.28 |
| Stochastic Oscillator | 96.56 | 84.74 |
Ubiquiti Inc is a seller of equipment and provides the related software platforms through web stores. The group develops technology platforms for high-capacity distributed Internet access, unified information technology, and consumer electronics for professional, home, and personal use. Its solutions are: high-performance networking technology for enterprises, service providers, and consumers. target the enterprise and service provider markets through a community of service providers, distributors, value-added resellers, webstores, systems integrators, and corporate IT professionals, which it refers to as the Ubiquiti Community. It targets consumers through digital marketing, including through webstores, retail chains, and, to a lesser extent, the Ubiquiti Community.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.